Avacta : ALS-6000-101 Phase 1a Three-Weekly Dose Escalation Safety Study Data -December 13, 2023 at 02:03 am EST
The data confirm the pre|CISIONTM platform's ability to transform the safety profile of doxorubicin through tumour targeting Cohort 7, the final cohort in the three-weekly dose...
Source: marketscreener.com